NCT00513695 - Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

August 31, 2012

Study Completion Date

October 16, 2017

Conditions

Inflammatory Breast CancerMale Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer

Interventions

DRUG

sunitinib malate

Given PO

DRUG

paclitaxel

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

cyclophosphamide

Given PO

BIOLOGICAL

filgrastim

Given SC

PROCEDURE

therapeutic conventional surgery

Undergo surgery

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

flow cytometry

Correlative studies

Trial Locations (7)

83712

Saint Luke's Mountain States Tumor Institute, Boise

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

98273

Skagit Valley Hospital, Mount Vernon

98362

Olympic Medical Center, Port Angeles

99508

Anchorage Oncology Centre, Anchorage

Katmai Oncology Group, Anchorage

85724-5024

Arizona Cancer Center, Tucson

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER